DRAK2 Antibody – Pre-diluted Summary
Synthetic peptide corresponding to C-terminal of of human DRAK2 protein.
This product is specific for DRAK2
IgG
Polyclonal
Rabbit
STK17B
Immunogen affinity purified
Test in a species/application not listed above to receive a full credit towards a future purchase.
Learn about the Innovators Reward
Applications/Dilutions
- Immunohistochemistry 1:10-1:500
- Immunohistochemistry-Paraffin Neat
IHC-P: Ready diluted. Not tested in other applications.Optimal dilutions/concentrations should be determined by the end user.
Reactivity Notes
This product is specific for Human.
Packaging, Storage & Formulations
Store at 4C. Do not freeze.
Prediluted antibody
No Preservative
Immunogen affinity purified
Alternate Names for DRAK2 Antibody – Pre-diluted
- DAP kinase-related apoptosis-inducing protein kinase 2
- DRAK2
- DRAK2death-associated protein kinase-related 2
- EC 2.7.11
- EC 2.7.11.1
- serine/threonine kinase 17b (apoptosis-inducing)
- serine/threonine kinase 17b
- serine/threonine-protein kinase 17B
- STK17B
Background
Protein kinases play important roles in the signal transduction in response to a variety of external stimuli. Recently, several protein kinases have been identified that may also be involved in apoptotic process. Overexpression of a serine/threonine kinase, ZIP kinase can cause the morphological changes typical of apoptosis in NIH 3T3 cells (1). Sanjo et al, have identified two new protein kinases DRAK1 and DRAK2 (Death Receptor Associated Kinase 1 and 2) (1). Both DRAKs and ZIP kinase share significant homology at the amino acid level (1,2). The kinase domains of both DRAKs, ZIP kinase are homologous to DAP (Death-associated protein) kinase, which is involved in the apoptotic signaling induced by interferon-g. Overexpression of DRAKs in NIH 3T3 cells lead to apoptosis. These transfection experiments suggest that C-terminal domain of DRAKs are important for induction of apoptosis.
Limitations
This product is for research use only and is not approved for use in humans or in clinical diagnosis. Primary Antibodies are guaranteed for 1 year from date of receipt.